CASE REPORT article
Front. Med.
Sec. Family Medicine and Primary Care
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1657069
This article is part of the Research TopicUncommon or Rare Forms of Diabetes: From Diagnosis to ManagementView all 4 articles
Continuous Intraperitoneal Insulin Infusion as a valuable approach in patients with unstable Type 1 Diabetes: two case reports and a mini review of the literature
Provisionally accepted
Erika Pedone1
Amelia Caretto1*
Giulio Belfiori2
Anna Zanardini1Sergio Di Molfetta3
Luigi Laviola3
Francesco Giorgino3
Lorenzo Piemonti1,4
Marina Scavini1
Andrea Laurenzi1,4- 1Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy
- 2Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy
- 3Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, 70124 Bari, Italy, Milan, Italy
- 4Universita Vita Salute San Raffaele, Milan, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a valid therapeutic option to achieve good glycemic control for patients with unstable type 1 diabetes and subcutaneous insulin resistance, mainly due to the absorption of insulin through the portal venous system. This route improves hepatic uptake and reduces peripheral plasma insulin levels, also optimizing glucagon secretion and hepatic glucose production. CIPII can lead to better blood glucose control and more predictable insulin profiles, especially after meals, compared to subcutaneous injections. Therefore, some studies suggest that CIPII may reduce the risk of hypoglycemia compared to subcutaneous insulin as well as improving patient satisfaction. Actually, among CIPII delivery systems, DiaPort particularly stands out for its low side effects, proven clinical efficacy, and potential for integration into closedloop systems.
Keywords: Continuous intraperitoneal insulin infusion, Hypoglycemia, subcutaneous insulin resistance, Glycemic variability, type 1 diabetes
Received: 30 Jun 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Pedone, Caretto, Belfiori, Zanardini, Di Molfetta, Laviola, Giorgino, Piemonti, Scavini and Laurenzi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Amelia Caretto, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.